GlassScriptPhysician profile
James D Geyer
NPI 1821056789
$61,463.81
in general payments reported to CMS, 2019-2025
66 companies · $4,471 in 2025
The $4,471 reported for 2025 was more than what 88% of Sleep Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $337).
See the full distribution for Sleep Medicine (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $775 · 2020: $1,134 · 2021: $1,055 · 2022: $13K · 2023: $28K · 2024: $14K · 2025: $4,471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $31K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,178 · Food and Beverage: $4,107 · Honoraria: $3,125 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,875 · Education: $153 · Travel and Lodging: $57.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $31,280.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,177.50 |
| Food and Beverage | $4,107.35 |
| Honoraria | $3,125.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,875.00 |
| Education | $153.09 |
| Travel and Lodging | $57.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $30,706.68 | 2023-2025 | Sunosi |
| Jazz Pharmaceuticals INC. | $11,906.11 | 2019-2025 | |
| Idorsia Pharmaceuticals US INC | $6,559.07 | 2023 | Quviviq |
| Biogen, INC. | $5,497.24 | 2019-2025 | Tysabri, Vumerity, Avonex |
| Abbvie INC. | $870.44 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $640.49 | 2019-2025 | |
| Harmony Biosciences LLC | $599.65 | 2020-2025 | Wakix |
| Ucb, INC. | $368.20 | 2020-2025 | Briviact, Rystiggo, Fintepla |
| Amgen INC. | $268.02 | 2019-2025 | Uplizna |
| Allergan, INC. | $257.12 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $215.34 | 2019-2025 | Austedo Xr, Austedo |
| Sunovion Pharmaceuticals INC. | $211.21 | 2019-2021 | |
| Upsher-Smith Laboratories LLC | $202.97 | 2019-2021 | |
| Emd Serono, INC. | $194.88 | 2019-2025 | Mavenclad |
| Sk Life Science, INC. | $185.99 | 2020-2025 |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Geyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.